Gain Therapeutics Inc
GANX
NASDAQ. Currency in USD
2.97 -0.01 ( -0.34% )
Market Cap.
35.29M
Beta (5Y monthly)
-
Price/Earnings
-
EPS (TTM)
-1.34
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
90,021
1y Target Est.
7.80
Day's Range
52 Week's Range
Historical Summary
Performance
1 Month
-3.71%
YTD
-45.30%
1Y
-49.66%
EPS growth
1Y
-12.61%
Share Buybacks
3 Months
-0.00%
6 Months
-0.00%
1Y
-0.06%
2Y
-343.18%
3Y
-144.07%
About Gain Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Website
https://www.gaintherapeutics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
11.88M
Employees
25
Address
4800 Montgomery Lane, Bethesda, MD, United States, 20814
Latest news
Expert Ratings for Gain Therapeutics
Analysts have provided the following ratings for Gain Therapeutics (NASDAQ:GANX) within the last quarter:
Bullish...
By Benzinga - 7 weeks ago
Analyst Ratings for Gain Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Gain Therapeutics (NASDAQ:GANX)...
By Benzinga - 7 weeks ago

Medtronic To $85? Plus Oppenheimer Slashes PT On This Stock By 67%
Barclays cut Medtronic plc (NYSE: MDT) price target from $90 to $85. Medtronic shares gained...
By Benzinga - 9 weeks ago

Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10....
By Benzinga - 11 weeks ago

AMD To Rally Around 39%? Here Are 5 Other Price Target Changes For Monday
Baird raised Advanced Micro Devices, Inc. (NASDAQ: AMD) price target from $65 to $100. ....
By Benzinga - 11 weeks ago

Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for...
By Zacks Investment Research - 11 weeks ago
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small...
By GlobeNewswire Inc. - 11 weeks ago

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for...
By Zacks Investment Research - 11 weeks ago